C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.
The Translational Therapeutics Accelerator (TRxA) by the Critical Path Institute (C-Path) is a not-for-profit global drug discovery and development program. It aims to support academic scientists in advancing new therapeutics from the laboratory to patients. This includes providing resources and guidance for developing comprehensive data packages for potential drug candidates, and engagement with contract research organizations for critical discovery phase experiments. The TRxA BRIDGe Awards focus on translating early-stage novel therapeutics into IND supporting data packages to facilitate licensing opportunities, specifically for projects in early lead optimization through to IND-enabling studies of small molecule therapeutics. Biologics, peptides, antibodies, cell and gene therapies, diagnostic and medical devices, and drug repurposing initiatives are currently not supported. Open to faculty at universities and non-profit institutions worldwide, the awards are not limited to specific therapeutic indications and cover three stages of translational projects.